Conference Menu

Overview
Day 1
Day 2
Register 
PDF Download
Short Courses
General Information 
Posters  
Hotel & Travel 
Supporter & Exhibitor 
Press Pass 
Request Brochure
Archives 

Podcasts 

Future Diagnostics

 

CHAO-Family-banner.jpg 


 

SMP mini Banner 

We wish to thank the following for their educational grant in support of this activity: 

Axxin 
KMC Systems 

Lead Supporting Publications: 

Bio-IT World 

Genetic Engineering &
Biotechnology News 

Nature 

Science 

The Scientist 

Supporting Publications: 

Drug Discovery News 

Genome Technology 

INSIGHT Pharma Reports 

Pharma Voice 

Web Partners: 

BioSpace.com 

genomeweb 

Presented by the Chao Family Comprehensive Cancer Center and Cambridge Healthtech Institute and held at the University of California, Irvine Student Center 

A number of breakthrough technologies are being incorporated into novel diagnostics to detect a range of molecular and protein biomarkers.  The diagnostic methods applied will include PCR, microarrays, sequencing, proteomics, methylation, and mutation detection. This meeting will highlight the next generation of diagnostic platforms that encompass the latest trends in microfluidics, point-of-care technologies, in vivo sensing, and consumer-driven products.  A panel of experts will focus on translation to the medical community and the key to success in implementation.

Topics include:CME Banner 

  • Microfluidic Technology and Business Trends
  • Point-of-Care Diagnostics
  • Nanotechnology Advances
  • Innovation in Microfluidics
  • In vivo Diagnostic Imaging
  • Recent Approvals of Companion Diagnostics

Scientific Advisory Board: 

  • John C. Carrano, Ph.D., President, Carrano Consulting, LLC
  • John J. Krolewski, M.D., Ph.D., Professor, Pathology & Laboratory Medicine, University of California, Irvine
  • Young Jik Kwon, Ph.D., Associate Professor, Department of Pharmaceutical Sciences, Department of Chemical Engineering and Materials Science, University of California, Irvine
  • Frank L. Meyskens, Jr., M.D., Director, Chao Family Cancer Center, University of California, Irvine
  • Edward L. Nelson, M.D., FACP, Chief, Heme/Onc Division, Associate Professor, Medicine and of Molecular Biology & Biochemistry, University of California, Irvine
  • Jennifer Prescher, Ph.D., Assistant Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
  • Gregory A. Weiss, Ph.D., Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine | Conference Chairman 

Testimonials

Testimonials

Pre-Conference Short Courses

Sunday, April 15: 1-4pm

12:00-1:00pm Short Course Registration

Microfluidics Technology and Market Trends*

In recent years, microfluidic and micro/nano technologies have transformed research and experienced impressive market growth allowing novel applications and market avenues. The impact of these enabling technologies will make it essential to adapt current strategies to meet future demands. This course will bring attendees up to date on technological advances, commercial applications of microfluidic technology, and market trends. Macroeconomic and regulatory aspects in the commercialization of new diagnostics products based on those micro technologies are becoming more and more urgent topics in the invention and development of new products. An overview of the microfluidic market for in vitro diagnostics will be presented as well as keys to market entry and future perspectives.

Speakers: 

Richard Selden, M.D., Ph.D., CEO, NetBio
Ali Tinazli, Director, Business Development & Sales, BioSciences - North America, Sony DADC Austria AG

Leanna Levine, Ph.D., President and CEO, ALine, Inc.

 

Click here for a detailed agenda

*Separate Registration Required    
*This course is not CME accredited 

 

Tuesday, April 17 | 6:30 – 8:30 pm

Guidelines for Commercial Launch of Novel Diagnostics 

This short course is focused on development of molecular diagnostics as they make their way from identification of a medical need through to commercial launch. The course will emphasize identification of critical hurdles that when addressed early, can materially accelerate progress. Vital areas to be addressed include disease management, validation, reimbursement strategies including provider engagement, regulatory pathway decisions and education of the medical community. Examples and case studies of diagnostic companies will be shared to illustrate a real world roadmap including:

  • Disease Management
  • Assay Validation
  • Regulatory Pathways and Considerations
  • Reimbursement
  • Acceptance and Adoption

Instructors:
Bill Cook, Principal, WECA
Dwight Denham, MBA, Director, Clinical Research, Health Economics &. Reimbursement Affairs (CHRA), Beckman Coulter, Inc.


*Separate Registration Required
*This course is not CME accredited